The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...
Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...
The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...
Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback